See more : GSR II Meteora Acquisition Corp. (GSRMW) Income Statement Analysis – Financial Results
Complete financial analysis of PCL, Inc. (241820.KQ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PCL, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
- Cheviot Company Limited (CHEVIOT.BO) Income Statement Analysis – Financial Results
- United Overseas Bank Limited (UOVEY) Income Statement Analysis – Financial Results
- Alto Neuroscience, Inc. (ANRO) Income Statement Analysis – Financial Results
- MedinCell S.A. (MDCLF) Income Statement Analysis – Financial Results
- CytomX Therapeutics, Inc. (CTMX) Income Statement Analysis – Financial Results
PCL, Inc. (241820.KQ)
About PCL, Inc.
PCL, Inc. provides multiplex in vitro diagnostic (IVD) products and platform services. The company offers multiplex antibody and antigen diagnostic kits for the detection of antibodies to human immunodeficiency virus (HIV) 1 and 2, HBV, hepatitis C virus (HCV), and human T-lymphotropic virus 1 and 2, as well as antigens to HIV p24, HCV core, and HBV surface in human serum or plasma. It also provides Ai, an influenza A/B typing rapid diagnostic test kit; Cancer6, a multiple tumor markers screening kit; and sciLINER LATERAL FLOW DISPENSER, a dispenser for membrane materials with active visual drop volume control. In addition, the company offers platform services, such as sol-gel spotting service that immobilizes the customer's requested material using the SolB reagent; and SG ID service, which provides customers with a molecule of interest immobilized in the SolB reagent and identified. PCL, Inc. is headquartered in Seoul, South Korea.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 8.43B | 37.22B | 46.15B | 53.68B | 35.81M | 128.54M | 506.14M | 588.75M | 243.02M |
| Cost of Revenue | 11.51B | 31.03B | 57.94B | 19.60B | 1.14B | 687.03M | 496.92M | 293.59M | 160.01M |
| Gross Profit | -3.08B | 6.19B | -11.79B | 34.08B | -1.10B | -558.49M | 9.23M | 295.16M | 83.01M |
| Gross Profit Ratio | -36.58% | 16.62% | -25.56% | 63.49% | -3,074.66% | -434.49% | 1.82% | 50.13% | 34.16% |
| Research & Development | 1.72B | 3.50B | 4.83B | 11.01B | 5.76B | 6.98B | 1.37B | 2.35B | 1.07B |
| General & Administrative | 808.07M | 853.81M | 906.55M | 572.86M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 3.62B | 7.85B | 5.09B | 1.87B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 4.43B | 10.99B | 9.15B | 794.22M | 2.69B | 881.04M | 2.73B | 331.44M | 379.46M |
| Other Expenses | 0.00 | 133.30M | -111.67M | 76.93M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 13.05B | 14.49B | 13.97B | 11.80B | 8.45B | 7.86B | 4.10B | 2.68B | 1.44B |
| Cost & Expenses | 24.56B | 45.52B | 71.91B | 31.41B | 9.59B | 8.54B | 4.59B | 2.97B | 1.60B |
| Interest Income | 664.10M | 1.37B | 160.65M | 6.01M | 51.23M | 28.40M | 89.58M | 20.48M | 44.22M |
| Interest Expense | 2.50B | 4.22B | 2.98B | 387.00M | 99.13M | 2.00 | 7.91M | 32.28M | 46.47M |
| Depreciation & Amortization | 2.87B | 2.59B | 2.03B | 1.35B | 1.11B | 602.71M | 246.33M | 100.57M | 49.68M |
| EBITDA | -13.78B | 2.80B | -26.66B | 21.25B | -6.75B | -5.17B | -3.61B | -2.21B | -1.77B |
| EBITDA Ratio | -163.47% | -15.36% | -51.43% | 44.01% | -23,573.02% | -6,077.80% | -758.81% | -387.63% | -539.96% |
| Operating Income | -16.13B | -8.30B | -25.77B | 22.28B | -9.55B | -8.42B | -4.09B | -2.38B | -1.36B |
| Operating Income Ratio | -191.37% | -22.31% | -55.83% | 41.50% | -26,678.73% | -6,546.68% | -807.47% | -404.72% | -560.40% |
| Total Other Income/Expenses | -4.23B | 4.23B | -5.91B | -2.77B | 1.59B | 2.64B | 217.76M | 42.19M | -502.27M |
| Income Before Tax | -20.37B | -4.01B | -31.67B | 19.51B | -7.97B | -5.77B | -3.87B | -2.34B | -1.86B |
| Income Before Tax Ratio | -241.59% | -10.78% | -68.63% | 36.34% | -22,244.14% | -4,489.80% | -764.45% | -397.55% | -767.08% |
| Income Tax Expense | -81.44M | 6.31M | -2.90M | -1.00 | 3.00 | 3.00 | -3.00 | 4.00 | 2.00 |
| Net Income | -20.32B | -4.02B | -31.67B | 19.51B | -7.97B | -5.77B | -3.87B | -2.34B | -1.86B |
| Net Income Ratio | -241.03% | -10.79% | -68.63% | 36.34% | -22,244.14% | -4,489.80% | -764.45% | -397.55% | -767.08% |
| EPS | -500.26 | -113.40 | -929.96 | 603.73 | -262.06 | -192.09 | -132.28 | -78.01 | -62.13 |
| EPS Diluted | -500.26 | -113.40 | -929.96 | 584.99 | -262.06 | -192.09 | -132.28 | -78.01 | -62.13 |
| Weighted Avg Shares Out | 40.62M | 35.43M | 34.05M | 32.31M | 30.40M | 30.04M | 29.25M | 30.00M | 30.00M |
| Weighted Avg Shares Out (Dil) | 40.62M | 35.43M | 34.05M | 34.04M | 30.40M | 30.04M | 29.25M | 30.00M | 30.00M |
Source: https://incomestatements.info
Category: Stock Reports